227. オスラー病 Osler disease Clinical trials / Disease details
臨床試験数 : 56 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05406362 (ClinicalTrials.gov) | July 18, 2022 | 10/5/2022 | Assess Safety and Efficacy of VAD044 in HHT Patients | A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Safety and Efficacy of Two Doses of VAD044 in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia (HHT) | Drug: VAD044 | Vaderis Therapeutics AG | NULL | Recruiting | 18 Years | N/A | All | 80 | Phase 1 | United States;Canada;Italy;Netherlands;Spain |